CC vs CSTM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Chemours Company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 17.51. While the stock has seen a massive 1-year price surge of 119.6%, this momentum is decoupled from fundamentals, as evidenced by a negative ROE of -93.80% and shrinking revenue. The dividend is unsustainable with a payout ratio of 555.56%, and the current price of $26.61 already exceeds the analyst target price of $21.67. Overall, the company appears to be in a high-risk state with significant solvency concerns.
CSTM presents a dichotomy between explosive growth and deteriorating fundamental value. While the Piotroski F-Score of 4/9 indicates stable but mediocre financial health, the stock is trading at a significant premium to its Graham Number ($17.43) and Intrinsic Value ($13.44). Despite a very attractive PEG ratio of 0.40 and strong ROE of 32.39%, the combination of aggressive insider selling by the CEO and CFO and a high Debt/Equity ratio (2.12) suggests the current price may be overextended.
Compare Another Pair
CC vs CSTM: Head-to-Head Comparison
This page compares The Chemours Company (CC) and Constellium SE (CSTM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.